TOI Q1 2026 Earnings Transcript

The Oncology Institute reported Q1 revenue of $147.4 million, up 41.2% year over year, with Specialty Pharmacy revenue surging 77.6% to $87.5 million and Florida turning profitable ahead of plan. Management reaffirmed full-year 2026 revenue guidance of $630 million-$650 million and adjusted EBITDA of $0-$9 million, while raising free cash flow guidance to $5 million-$15 million from prior negative-to-breakeven expectations. The company also highlighted nearly $2 million of Medicare savings under CMS’s EOM model and $2 million of AI-driven operating expense savings on track for 2026.

Analysis

The market is likely underestimating how quickly TOI is converting scale into operating leverage. The key second-order effect is that capitation growth is now feeding three profit pools at once: clinic economics, pharmacy attachment, and payer credibility, which should lower the cost of winning additional delegated lives. That creates a compounding loop in Florida where each incremental member improves utilization visibility, strengthens the portal workflow, and increases capture of non-risk pharmacy revenue without adding much fixed cost.

The more interesting signal is that pharmacy is becoming the economic flywheel rather than a sidecar. A 12% decline in revenue per fill alongside flat pharmacy gross margin implies the business is absorbing a richer, more strategic mix while preserving unit economics; if attachment keeps improving, the revenue mix should keep shifting toward higher-conviction, clinically routed fills. The portal rollout is not just an efficiency tool; it is a distribution control point that can raise switching costs for affiliated providers and make TOI harder to displace in delegated markets.

The main risk is that the story depends on execution staying ahead of the scaling curve. The company is carrying meaningful refinancing risk and is still early in proving that Florida-level economics can replicate into other states; if MLR drifts even modestly above target as the new lives ramp, the equity rerates quickly because the market is pricing this as a clean operating inflection. The free-cash-flow upgrade looks quality-improving, but it is also supplier-driven, so investors should treat it as more durable than EBITDA only if working-capital behavior stays benign over the next 2-3 quarters.

Key Decisions for Investors

• Go long TOIIW into the next 1-2 quarters on the thesis that Florida delegation and pharmacy attachment are creating an operating leverage inflection; target a 20-30% upside window if the market re-rates toward profitable growth, but size modestly given refinancing overhang.
• Use a pair trade: long TOIIW / short EVH for 3-6 months. TOI is showing better capitation economics and tighter care delivery control; EVH is more exposed to market skepticism around medical-cost trends. Risk: if broader managed-care multiples de-rate on utilization concerns, both legs can move against you.
• Add on any post-earnings pullback only if management preserves the 2026 EBITDA range and confirms no deterioration in Florida MLR during Q2. This is a catalyst-sensitive name; the best entry is likely after the market digests the Q3 portal launch and live county expansion.
• Avoid chasing with common-equity-sized risk until the convertible note refi is clarified. If the refinancing lands on tolerable terms, the equity could gap higher; if it comes with punitive covenants or dilution, the stock’s upside is capped despite operational momentum.
• For higher-conviction upside exposure, consider a call spread in TOIIW with 3-6 month duration. The payoff is asymmetric if delegated lives and portal-driven Part D capture outperform, while premium paid limits damage if execution slips or the refi disappoints.